maprotiline has been researched along with opipramol in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Cardoso, FC; Duggan, PJ; Kuiper, MJ; Lewis, RJ; Schmit, M; Tuck, KL | 1 |
| Berger, M; Braun, JS; Geiger, R; Schäffer, S; Wehner, H | 1 |
3 other study(ies) available for maprotiline and opipramol
| Article | Year |
|---|---|
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Inhibition of N-type calcium ion channels by tricyclic antidepressants - experimental and theoretical justification for their use for neuropathic pain.
Topics: | 2022 |
Hepatitis caused by antidepressive therapy with maprotiline and opipramol.
Topics: Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Chemical and Drug Induced Liver Injury; Depressive Disorder; Humans; Liver Function Tests; Male; Maprotiline; Middle Aged; Opipramol | 1998 |